Uncategorized

Early Participant Snapshot — ACCESS ASIA Spring (April 27, Shanghai)

biotochinaby

On April 27, ACCESS ASIA Spring BD Salon & Reception will bring together a targeted group of cross-border biotech and pharma decision-makers.

Who’s Already Joined

Confirmed participants to date include:

  • Pfizer — S&E Lead (I&I / China for China)
  • Pfizer — China Internal Medicine S&E Lead
  • Boehringer Ingelheim — Head of Eye Health & RBB
  • AstraZeneca — Senior Manager, Digital Patient Pathway
  • Insmed — Director, BD
  • Marubeni — BD Group Manager
  • Sofinnova Partners — Partner
  • BeOne Medicines — Managing Director, Bioventures
  • Betta Pharmaceuticals — Director, Strategic Collaboration
  • Salubris — CSO
  • Mabwell — External Innovation / Head of BD
  • EDBI — Partner
  • Euclidean Capital — Investor
  • Brandon Capital — Senior Investment Manager

Additional participants across pharma, biotech, and investment are being confirmed on a rolling basis.

Agenda | Designed for Focused Interaction

April 27, 2026 | Shanghai

Afternoon
→ 1-on-1 Partnering Meetings  (time depending on meeting parties)
Closed-door pre-arranged meetings, the deadline to request meetings is April 20th. 

Evening
→ Cocktail Reception (4:30pm -6:30pm)

Participation & Positioning

As of April 7, 50+ participants are confirmed.
The session is designed for ~80 attendees, with review-based confirmation.

Registration

Option 1 — Apply to Attend (Non-Member)

  • Complimentary access to the event (for pharma, biotech, VC only, and by confirmation)
  • The opportunity to request 1-on-1 meetings with YAFO’s innovative assets

Please feel free to register for the event if you are interested.

Option 2 — Be ACCESS ASIA Bio (AAB) Member

  • Complimentary access to the event
  • Access to full attendee list
  • Priority meeting scheduling
  • Ongoing cross-border BD opportunities

You may click here to learn more about the ACCESS ASIA Bio membership.

Beyond the Event: ACCESS ASIA Bio

ACCESS ASIA Spring is part of ACCESS ASIA Bio (AAB) —
a curated cross-border BD ecosystem supported by YAFO Capital

For companies actively engaging in Asia–global partnerships, AAB provides:

  • Prioritized access to events like ACCESS ASIA Spring
  • Early visibility into participants and structured 1-on-1 meetings
  • Ongoing BD opportunities and ecosystem intelligence
  • Targeted introductions beyond a single event cycle

To learn more, inquire here: ACCESS ASIA Bio (AAB) Team | accessasiabio@gmail.com

The intent is not just one meeting —
but continuous, structured engagement across the year.

To become an ACCESS ASIA Bio member, apply here:
accessasiabio@gmail.com

Ahead of a busy ChinaBio week,
early, focused conversations often shape what follows.

FOLLOW US ON WECHAT & LINKEDIN